The evolving role of immunotherapy in prostate cancer

被引：11

作者：

Cordes, Lisa M. ^{[1
]}

Gulley, James L. ^{[2
]}

Madan, Ravi A. ^{[2
]}

机构：

[1] NIH, Clin Ctr, Bldg 10, Bethesda, MD 20892 USA

[2] NCI, Genitourinary Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

来源：

CURRENT OPINION IN ONCOLOGY | 2016年 / 28卷 / 03期

关键词：

immunomodulating agents; immunotherapy; prostate cancer; therapeutic cancer vaccine; PHASE-II TRIAL; SIPULEUCEL-T; ANDROGEN RECEPTOR; ANTITUMOR EFFICACY; CLINICAL-TRIAL; DOUBLE-BLIND; VACCINE; SURVIVAL; DOCETAXEL; CHEMOTHERAPY;

D O I：

10.1097/CCO.0000000000000281

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of reviewIn recent clinical trials, immunotherapeutic agents have demonstrated promising results for the treatment of prostate cancer. This review discusses emerging immunotherapies for prostate cancer and their evolving role in sequencing and combination therapy.Recent findingsTherapeutic vaccines including PROSTVAC and DCVAC/PCa have completed promising phase 2 trials for the treatment of prostate cancer and phase 3 trials are underway. Recent evidence supports a synergistic relationship between immunotherapy agents themselves, antiandrogens and with cytotoxic chemotherapy. Prostate cancer patients with good prognostic factors, such as minimal disease burden, appear to achieve the optimal benefit from immunotherapy.SummaryTherapeutic cancer vaccines and immunomodulating agents have demonstrated activity in the treatment of prostate cancer. Immunotherapies may alter the prostate tumor microenvironment and ongoing studies aim to provide guidance on effective sequencing and combination strategies.

引用

页码：232 / 240

页数：9

共 61 条

[1]

Adams S, 2007, J CLIN ONCOL, V25

[2]

[Anonymous], J CLIN ONCOL

[3]

Antonarakis ES., 2015, J. Clin. Oncol, V33

[4] Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway [J].